MODEL VERDICT
Avadel Pharmaceuticals plc (AVDL)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | NEUTRAL | 0.13 | $21.64 | CURRENT | — |
| Apr 24, 2026 | NEUTRAL | 0.13 | $21.64 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.13 | $21.64 | CURRENT | — |
| Apr 16, 2026 | NEUTRAL | 0.13 | $21.64 | CURRENT | — |
| Apr 10, 2026 | NEUTRAL | 0.13 | $21.64 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Forward P/E 6 analyst estimates | $7.83 | -63.8% | 20% | A- | Analyst Est. |
| EV To Revenue 9 industry peers | $8.33 | -61.5% | 4% | B | Data |
| Price / Sales 9 industry peers | $10.55 | -51.2% | 3% | B | Model Driven |
| Weighted Output Blended model output | $9.31 | -57.0% | 100% | 54 | SIGNIFICANTLY OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 10.93 | 11.83 | 2.52 | 17.54 | 7.07 |
| P/B Ratio | 13.88 | 12.90 | 2.26 | 34.64 | 12.53 |
| P/S Ratio | 13.71 | 5.91 | 0.93 | 40.48 | 16.03 |
Based on our peer multiples analysis with 8 valuation metrics, the model estimates AVDL's fair value at $9.31 vs the current price of $21.64, implying -57.0% downside potential. Model verdict: Significantly Overvalued. Confidence: 54/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $9.31 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $6.82 (P10) to $12.82 (P90), with a median of $9.57.
AVDL's current P/E of -42.4x compares to the industry median of 22.7x (6 peers in the group). This represents a -286.9% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
14 analysts cover AVDL with a consensus rating of Buy. The consensus price target is $22.50 (range: $22.50 — $22.50), implying +4.0% upside from the current price. Grade breakdown: Strong Buy (0), Buy (8), Hold (6), Sell (0), Strong Sell (0).
The model confidence score is 54/100, based on: data completeness (6), peer quality (25), historical depth (16), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for AVDL.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.